Healthtake

Beijing Healthtake Biopharmaceutical is a clinical-stage biotechnology company headquartered in Beijing, China, focused on the discovery and development of innovative biologics for oncology and autoimmune diseases. The company utilizes its proprietary antibody engineering platforms to create a robust pipeline of monoclonal antibodies, bispecific antibodies, and fusion proteins. Its lead candidate, HT-101, is a humanized anti-CD38 monoclonal antibody currently in Phase 1/2 clinical trials for the treatment of relapsed or refractory multiple myeloma. Additionally, Healthtake is advancing several other programs, including HT-102 targeting Claudin 18.2 and HT-103, a bifunctional fusion protein targeting PD-L1 and TGF-beta. The company aims to provide high-quality, affordable innovative medicines to patients globally through its integrated R&D and manufacturing capabilities.